Kimberly A. Reed
About Kimberly A. Reed
Independent director at HASI since 2023; age 54. Serves on the Nominating, Governance & Corporate Responsibility (NGCR) Committee and the Finance & Risk Committee. Former Chairman, President, and CEO of the Export-Import Bank of the United States (EXIM) from May 2019 to January 2021. Education: JD (West Virginia University College of Law); BS Biology and BA Government (West Virginia Wesleyan College); NACD Certified Director; CFR life member; recipient of DoD Medal for Distinguished Public Service.
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Export-Import Bank of the United States (EXIM) | Chairman of the Board, President & CEO | May 2019–Jan 2021 | Led the U.S. $135B export credit agency; supported U.S. companies in global markets |
| U.S. Treasury | Senior Advisor to Secretaries Henry Paulson & John Snow | — | Advisory roles on finance and policy |
| CDFI Fund (U.S. Treasury) | CEO | — | Oversight of community development finance initiatives |
| International Food Information Council Foundation | President | — | Focused on agriculture, nutrition, health, sustainability |
Note: Specific dates for roles marked “—” were not disclosed.
External Roles
| Organization | Role | Tenure | Committees/Notes |
|---|---|---|---|
| Takeda Pharmaceutical Company Limited | External Director | Since June 2022 | Public company board |
| Momentus Inc. | Independent Director | Since Aug 2021 | Public company board |
| American Swiss Foundation | Director | Current | Non-profit board |
| Council on Competitiveness; Atlantic Council Freedom & Prosperity Center | Distinguished Fellow | Current | Policy and competitiveness focus |
| Hudson Institute Alexander Hamilton Commission; Krach Institute Advisory Council; Indiana University SPH Dean’s Alliance | Advisory roles | Current | Technology/security/public health engagement |
Board Governance
- Independence: Board affirmatively determined Reed is independent under NYSE standards and Company Independence Standards. Ten of twelve current directors are independent; Lead Independent Director is Teresa M. Brenner.
- Committee assignments: NGCR Committee and Finance & Risk Committee; both comprised solely of independent directors.
- Executive sessions: Independent directors meet in executive sessions at least four times per year, presided over by the Lead Independent Director.
- Attendance: 2024 meeting attendance—Board: 8 meetings, 95%; Audit: 9 meetings, 100%; Compensation: 8 meetings, 100%; Finance & Risk: 5 meetings, 100%; NGCR: 5 meetings, 90%. Individual director-level attendance was not disclosed.
- Years of service on HASI board: 2 years as of Record Date (April 7, 2025).
- Board structure: Separate Chair and CEO; majority vote policy for director elections; non-staggered board.
Fixed Compensation
| Component (2024) | Amount/Detail | Vesting/Timing |
|---|---|---|
| Annual cash retainer | $110,000 | Paid quarterly in arrears |
| Committee chair fees | $0 (not a chair) | — |
| Equity grant (standard program) | Targeted $145,000 annually, in LTIP units | Program structure |
| 2024 stock awards (actual) | $194,746 | Grant of 6,126 LTIP units at $31.79; vest June 6, 2025 |
| Other benefits | Reimbursement of board-related expenses; not eligible for employee savings/retirement plans | — |
| Ownership guidelines | Non-employee directors must hold ≥5× annual cash retainer; retain 100% of equity grants (net of taxes) until compliant | Reed has until 2028 to comply |
2025 chair/lead independent adjustments: Chair receives $100,000 incremental retainer; Lead Independent Director retainer increased to $35,000. No changes to general director cash retainer or targeted annual equity grants.
Performance Compensation
| Component | Performance Metric | Target | Actual/Payout Impact |
|---|---|---|---|
| Director LTIP equity (2024 grant) | None (time-based vesting only) | N/A | Vests June 6, 2025; no performance conditions disclosed |
Note: Non-employee director equity awards are time-based LTIP units; no director-specific performance metrics were disclosed.
Other Directorships & Interlocks
| Company | Industry | Role | Potential Interlock/Conflict Considerations |
|---|---|---|---|
| Takeda Pharmaceutical Company Limited | Pharmaceuticals | External Director | No disclosed related-party transactions with HASI; Company conflicts policy requires pre-approval of any potential conflicts |
| Momentus Inc. | Space/transport | Independent Director | No disclosed related-party transactions with HASI; conflicts managed via Code/Related Transactions Policy |
HASI’s Related Transactions Policy prohibits directors/officers/employees from engaging in transactions involving actual/potential conflicts unless pre-approved; no related-party transactions were disclosed for Reed.
Expertise & Qualifications
- Government and international finance; export credit and infrastructure finance leadership (EXIM Chair/CEO).
- Risk management and capital markets; corporate governance; strategic planning; senior leadership experience.
- Certified NACD Director; recognized for STEM leadership; CFR life member; DoD Medal for Distinguished Public Service.
Equity Ownership
| Metric | Value | Notes |
|---|---|---|
| Shares beneficially owned (as of Apr 7, 2025) | 9,567 | <1% of outstanding shares; address on file at HASI HQ |
| Unvested LTIP units (as of Dec 31, 2024) | 6,126 | 2024 director LTIP units vest June 6, 2025 |
| Ownership guidelines compliance | Not yet met | Deadline: 2028; must retain 100% of equity grants (net of taxes) until compliant |
| Hedging/pledging | Prohibited | Policy prohibits hedging, margin accounts, pledging of Company stock |
Governance Assessment
- Independence and committee roles: Reed strengthens independent oversight through NGCR and Finance & Risk committees overseeing sustainability, human capital, financing, and risk management.
- Attendance and engagement: Board and committee attendance levels in 2024 support effective oversight; independent director executive sessions held ≥4 times annually.
- Alignment and ownership: Equity grants in LTIP units with mandatory retention until meeting 5× retainer guideline promote alignment; Reed’s compliance deadline (2028) is standard for newer directors.
- Conflicts/related parties: No related-party transactions disclosed; robust conflicts policy requiring pre-approval of any potential conflicts; prohibition on director loans and hedging/pledging reduces alignment risk.
- RED FLAGS: Not currently at ownership guideline (deadline 2028), but mitigated by retention requirement; no pledging allowed; no director-specific performance metrics tied to equity grants (time-based grants standard for independent directors).
Overall signal: Reed’s regulatory, finance, and governance background complements HASI’s sustainability and risk oversight; independence, structured director pay, and strong conflicts policies support investor confidence, with ownership guideline progress to watch through 2028.